<SEC-DOCUMENT>0001213900-24-099835.txt : 20241119
<SEC-HEADER>0001213900-24-099835.hdr.sgml : 20241119
<ACCEPTANCE-DATETIME>20241119080032
ACCESSION NUMBER:		0001213900-24-099835
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241119
FILED AS OF DATE:		20241119
DATE AS OF CHANGE:		20241119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		241473398

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0221761-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of    November 2024</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font-style: normal; vertical-align: top; text-align: justify; background-color: rgb(204,238,255); font-weight: normal">
<td style="font-style: normal; width: 9%; text-align: left; font-weight: normal">99.1</td>
    <td style="font-style: normal; width: 1%; font-weight: normal"><b>&nbsp;</b></td><td style="font-style: normal; text-align: justify; width: 90%; font-weight: normal"><A HREF="ea022176101ex99-1_alterity.htm">Change of Company Secretary- ATH</A></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November 19, 2024</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea022176101ex99-1_alterity.htm
<DESCRIPTION>CHANGE OF COMPANY SECRETARY- ATH
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Change of Company Secretary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
&ndash; 19 November 2024: </B>Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;), has
announced the appointment of Abby Macnish Niven as Alterity&rsquo;s Company Secretary following her appointment as Chief Financial Officer
of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board and Management of Alterity thank Phillip
for his valuable contributions over the past several years and appreciate the foundation he helped establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms Macnish Niven was appointed as CFO on 30 September
2024 and has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults
to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce
and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of ASX Listing Rule 12.6, Ms
Macnish Niven will be the person responsible for communications between the Company and ASX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company&rsquo;s lead asset, ATH434,
has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple
System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology
of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please
visit the Company&rsquo;s web site at www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorisation &amp; Additional information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement was authorised by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor and Media Contacts: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61 452 510 255</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains &quot;forward-looking
statements&quot; within the meaning of section 27A of the identify such forward-looking statements by use of such words as &quot;expects,&quot;
&quot;intends,&quot; &quot;hopes,&quot; &quot;anticipates,&quot; &quot;believes,&quot; &quot;could,&quot; &quot;may,&quot; &quot;evidences&quot;
and &quot;estimates,&quot; and other similar expressions, but these words are not the exclusive means of identifying such statements.
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,
but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other
statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing
of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future
sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but
not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's
intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent rights and the uncertainty
of the Company freedom to operate. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Any forward-looking statement made by us in
this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 7@# 2(  A$! Q$!_\0
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M535Y[X5^(GA"R\):/:W'B"RCGALH4D1G.58( 0>/6N[LKVVU&RAO+.99K:9
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M@:TZU%3FM?S\SF_ X T!L #_ $B3I]:W[FYAL[:2XN)!'#&I9V/85@>"/^0
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M+VLW:2//!!]1T/O7IGA/]H V>G0V?B.PFN98E"_:[=AN<#NRG'/N#S7M6O\
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M\YTKXGW?_"16.B^)/#%WHLU^VRVE>3>CMV'08YP._45Z%/)Y-O)+C.Q"V/7
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ME9UIQD[Q_)+\AI6/G[0#XTAU?QW=^%)[()!J$CS0S1[I)""Y 3C&<9X-=?\
M!:RANM+U'Q1+J7V[5-5F_P!+^3;Y+*3\F/7G/IC%=_I7A_2]$N+Z?3K18);Z
M7SKE@Q/F/SSR>.IZ5'I'AC1]!N[RYTNS6VDO7WS[&;:[9)SM)P.IZ5O5Q,9Q
ME%*U[?AW)4;%3QUXC7PIX.U'5<CSDCV0 ]Y6X7]3GZ U\_3:C:0?#:RLK?2M
M<CU^SO/[2-Z]IB/S<_,2V<XV@<XZJ*^C];\.Z5XC@@@U:T6ZB@E$R(S$ ..
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?:1I45O.R[3*27?'H"Q) ^E%%>I&<DXK]+_)"2:/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
